How darolutamide works for advanced prostate cancer in Germany
Part of Cancer, Hormones & metabolism, Kidney & urinary clinical trials.
This study looks at how well a drug called darolutamide (a type of hormone therapy) works in everyday medical practice for men with advanced prostate cancer that has spread. It is for men who are already starting this treatment with their doctor and will help doctors understand how it works in real life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have advanced prostate cancer that has spread to other parts of the body (confirmed by a biopsy or scan)
- Your doctor has already decided to treat you with darolutamide plus standard hormone therapy (ADT) as part of your regular care
- You have not started darolutamide more than 30 days before joining this study
- You have not started standard hormone therapy (ADT) more than 12 weeks before starting darolutamide
- You have not had any other hormone or cancer treatment for your advanced prostate cancer before this
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a drug called darolutamide combined with standard hormone therapy for men whose prostate cancer has spread to other parts of the body and still responds to hormone treatment. The goal is to see if this combination helps control the cancer better than hormone therapy alone.
This trial tests a combination of precise radiation therapy (SBRT) and a drug called darolutamide for men whose prostate cancer has spread to a limited number of other parts of the body. The goal is to see if this approach can control the cancer effectively with fewer side effects.
This study looks at how safe and effective the combination of darolutamide (a tablet), hormone therapy (ADT), and chemotherapy (docetaxel) is for Japanese men with prostate cancer that has spread in a limited way (low volume). It observes people in regular medical care, not in a research setting.
This trial tests the drug darolutamide for men whose prostate cancer has spread and is no longer controlled by standard hormone therapy. It may be an option if you've already had certain hormone treatments for at least 12 months but your cancer is still progressing.
This study watches how well a drug called darolutamide works when combined with hormone therapy for men with prostate cancer that has returned after previous treatment. The goal is to understand if this combination helps prevent cancer spread and is safe to use.
This study looks at how well darolutamide and similar drugs work for men whose prostate cancer has just spread to other parts of the body. It aims to understand real-world outcomes in urology clinics.
Hear when a new Metastatic Hormone-sensitive Prostate Cancer (mHSPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.